Financial reports
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
10-Q
2021 Q2
Quarterly report
9 Aug 21
10-Q
2021 Q1
Quarterly report
3 May 21
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
Current reports
8-K
Amgen Successfully Completes Acquisition of Chemocentryx
20 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
18 Oct 22
8-K
Other Events
19 Sep 22
8-K
Amgen to Acquire Chemocentryx for $4 Billion In Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine
4 Aug 22
8-K
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
5 Jul 22
8-K
Departure of Directors or Certain Officers
9 Jun 22
8-K
ChemoCentryx Announces Changes to its Board of Directors
1 Jun 22
8-K
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
5 May 22
8-K
Other Events
3 May 22
8-K
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
1 Mar 22
Registration and prospectus
15-12G
Securities registration termination
31 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Oct 22
POSASR
Automatic shelf registration (post-effective amendment)
20 Oct 22
25-NSE
Exchange delisting
20 Oct 22
S-8
Registration of securities for employees
10 Aug 21
424B5
Prospectus supplement for primary offering
11 Jun 20
424B5
Prospectus supplement for primary offering
10 Jun 20
S-3ASR
Automatic shelf registration
10 Jun 20
S-3
Shelf registration
7 May 19
Proxies
DEFA14A
Additional proxy soliciting materials
7 Oct 22
DEFA14A
Additional proxy soliciting materials
19 Sep 22
DEFM14A
Proxy related to merger
14 Sep 22
PREM14A
Preliminary proxy related to merger
31 Aug 22
DEFA14A
Additional proxy soliciting materials
30 Aug 22
DEFA14A
Additional proxy soliciting materials
22 Aug 22
DEFA14A
Additional proxy soliciting materials
9 Aug 22
DEFA14A
Additional proxy soliciting materials
8 Aug 22
DEFA14A
Additional proxy soliciting materials
5 Apr 22
DEF 14A
Definitive proxy
5 Apr 22
Other
EFFECT
Notice of effectiveness
20 May 19
CORRESP
Correspondence with SEC
15 May 19
UPLOAD
Letter from SEC
14 May 19
CT ORDER
Confidential treatment order
7 Sep 18
CT ORDER
Confidential treatment order
21 Aug 17
CT ORDER
Confidential treatment order
29 Jun 17
CT ORDER
Confidential treatment order
20 Jun 17
CT ORDER
Confidential treatment order
16 Sep 16
EFFECT
Notice of effectiveness
28 Apr 16
CORRESP
Correspondence with SEC
26 Apr 16